Voleon Capital Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.42M Sell
121,416
-52,493
-30% -$858K 0.03% 393
2026
Q2
$3.39M Sell
173,909
-199,112
-53% -$3.61M 0.06% 271
2026
Q1
$6.95M Sell
373,021
-126,078
-25% -$2.09M 0.15% 148
2025
Q4
$6.58M Buy
499,099
+458,826
+1,139% +$5.41M 0.14% 161
2025
Q3
$289K Buy
+40,273
New +$2.1M 0.01% 730

Other funds holding MLTX

Voleon Capital Management's MLTX Position: Q3 2026 in Review

Voleon Capital Management reduced its MoonLake Immunotherapeutics (MLTX) stake by 30% in Q3 2026, selling an estimated $858K and leaving 121,416 shares worth $1.42M. The position accounts for 0.03% of the portfolio, ranked #393.

Voleon Capital Management first reported a position in MLTX in Q3 2025 and has held it in 5 quarters since. The position peaked at $6.95M in Q1 2026. 170 funds tracked by Wall St. Rank hold MLTX as of Q3 2026.

  • Voleon Capital Management held 121,416 shares of MoonLake Immunotherapeutics worth $1.42M as of Q3 2026.
  • Voleon Capital Management sold 52,493 MoonLake Immunotherapeutics shares in Q3 2026, an estimated $858K.
  • MoonLake Immunotherapeutics made up 0.03% of Voleon Capital Management's portfolio in Q3 2026, its #393 holding.
  • Voleon Capital Management first reported a position in MoonLake Immunotherapeutics in Q3 2025 and has held it in 5 quarters since.
  • Voleon Capital Management's MoonLake Immunotherapeutics position peaked at $6.95M in Q1 2026.
  • 170 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2026.

Based on Voleon Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.